Navigation Links
Dana-Farber receive $5.6 million grant to develop rapid countermeasures to infectious agents
Date:1/18/2011

BOSTON--Researchers at Dana-Farber Cancer Institute have received a $5.6 million grant from the Defense Advanced Research Projects Agency (DARPA) and the Army Research Office (ARO) to develop transient immunity against known, unknown, naturally occurring, or engineered disease-causing pathogens. The ultimate goal is to develop a viable countermeasure to an unknown pathogen within seven days of receiving it in a laboratory.

Wayne A. Marasco, MD, PhD, of the Department of Cancer Immunology and AIDS at Dana-Farber and an associate professor of Medicine at Harvard Medical School, is the project's principal investigator.

Since the mid 1990's, DARPA's Defense Sciences Office has pioneered advances across the full spectrum of bio-warfare defense needs, including the development of advanced diagnostics and medical therapies that are active against an entire range of infectious agents.

"This grant will support revolutionary advances in rapid response to naturally evolving and engineered pathogens," says Marasco. "DARPA has issued a challenge to develop a treatment to unknown threats in just seven days, and we are excited about the opportunity to meet this challenge."

Disease-causing pathogens can be spread through natural and intentional means. Factors responsible for the increase in newly emerging and re-emerging pathogens include increased animal-human interface, increased population densities and international travel, climate change as it affects migration of animals such as birds, some of which could be disease carriers and the narrowing of genetic diversity among food animal stocks.

In addition, the proliferation of genetic engineering technologies that can be easily redirected from beneficent to offensive purposes, and the covert biological sabotage of food animals are all great biodefense concerns.

"In the past, medical responses to large-scale disease outbreaks have been very slow," said Marasco. "Often it has taken many months to years to research and create medicines or vaccines, time barriers that often result in loss of life. This program gives us an opportunity to very rapidly provide ways to prevent infection and extend survival until long-term solutions are available."

Marasco will direct an international team of leading scientists and businesses engaged in the study of pathogen detection, screening, and therapeutic formulation and manufacturing. The team will pursue two parallel paths toward the program goals: First, to rapidly select broadly neutralizing phage antibodies for direct use as therapeutics for microbial infection; and Second, to investigate selective anti-idiotypic stimulation of B-cell precursors leading to secretion of antibodies with broad-spectrum, natural, anti-microbial activity.


'/>"/>

Contact: Bill Schaller
william_schaller@dfci.harvard.edu
617-632-5357
Dana-Farber Cancer Institute
Source:Eurekalert

Related biology news :

1. Dana-Farber oncologists present at ASCO GU -- predict prostate cancer survival using Source MDx test
2. Dana-Farber and sanofi-aventis establish cancer research alliance
3. Wistar Institute researcher receives New Innovator award from NIH
4. L-1 Identity Solutions Receives $5.9 Million Drivers License Contract Expansion from the State of Mississippi
5. Kount Receives Patent for Device Fingerprinting
6. American College of Medical Genetics receives $13.5M NIH contract
7. Carnegie Mellon to receive $900,000 from EPA for brownfields research
8. Penn State receives new NASA astrobiology grant
9. Salk scientist Fred H. Gage to receive the Keio Medical Science Prize
10. Global Viral Forecasting Initiative receives $11M to implement pandemic early warning system
11. Vidaza receives positve opinion from European CHMP
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/14/2016)... TEL AVIV, Israel , April 14, 2016 /PRNewswire/ ... in Behavioral Authentication and Malware Detection, today announced the ... has already assumed the new role. Goldwerger,s ... for BioCatch, on the heels of the deployment of ... In addition, BioCatch,s behavioral biometric technology, which discerns unique ...
(Date:3/29/2016)... , March 29, 2016 LegacyXChange, ... LegacyXChange "LEGX" and SelectaDNA/CSI Protect are pleased to announce ... used in a variety of writing instruments, ensuring athletes ... originally created collectibles from athletes on LegacyXChange will be ... of the DNA. Bill Bollander , ...
(Date:3/21/2016)... 22, 2016 Unique technology ... for superior security   Xura, ... of secure digital communications services, today announced it is ... offer enterprise customers, particularly those in the Financial Services ... voice authentication within a mobile app, alongside, and in ...
Breaking Biology News(10 mins):
(Date:6/24/2016)... ... ... While the majority of commercial spectrophotometers and fluorometers use the z-dimension of ... higher end machines that use the more unconventional z-dimension of 20mm. Z-dimension ... of the cuvette holder. , FireflySci has developed several Agilent flow cell product ...
(Date:6/23/2016)... ... June 23, 2016 , ... UAS LifeSciences, one of ... their brand, UP4™ Probiotics, into Target stores nationwide. The company, which has been ... Target to its list of well-respected retailers. This list includes such fine stores ...
(Date:6/23/2016)... June 23, 2016 A person commits a crime, ... scene to track the criminal down. An outbreak ... and Drug Administration (FDA) uses DNA evidence to track down ... Sound far-fetched? It,s not. The FDA has increasingly used ... investigations of foodborne illnesses. Put as simply as possible, whole ...
(Date:6/23/2016)... -- The Prostate Cancer Foundation (PCF) is pleased to announce 24 new ... prostate cancer. Members of the Class of 2016 were selected from a pool ... Read More About the Class of 2016 PCF Young Investigators ... ... ...
Breaking Biology Technology: